guest ::
| Home > Publications database > Application of quaternary 1,4-diazabicyclo[2.2.2]octan (DABCO) salts for SN2 “minimalist” radiofluorination > print |
| Home > Publications database > Application of quaternary 1,4-diazabicyclo[2.2.2]octan (DABCO) salts for SN2 “minimalist” radiofluorination > print |
| 001 | 911349 | ||
| 005 | 20240625201955.0 | ||
| 024 | 7 | _ | |a 10.1016/S0969-8051(22)00134-2 |2 doi |
| 024 | 7 | _ | |a 0969-8051 |2 ISSN |
| 024 | 7 | _ | |a 1872-9614 |2 ISSN |
| 037 | _ | _ | |a FZJ-2022-04641 |
| 082 | _ | _ | |a 570 |
| 100 | 1 | _ | |a Keuthen, Yannick |0 P:(DE-Juel1)186812 |b 0 |e Corresponding author |u fzj |
| 111 | 2 | _ | |a 24th International Symposium on Radiopharmaceutical Sciences |g iSRS 2022 |c Nantes |d 2022-05-29 - 2022-06-03 |w France |
| 245 | _ | _ | |a Application of quaternary 1,4-diazabicyclo[2.2.2]octan (DABCO) salts for SN2 “minimalist” radiofluorination |
| 260 | _ | _ | |c 2022 |
| 336 | 7 | _ | |a Conference Paper |0 33 |2 EndNote |
| 336 | 7 | _ | |a Other |2 DataCite |
| 336 | 7 | _ | |a INPROCEEDINGS |2 BibTeX |
| 336 | 7 | _ | |a conferenceObject |2 DRIVER |
| 336 | 7 | _ | |a LECTURE_SPEECH |2 ORCID |
| 336 | 7 | _ | |a Conference Presentation |b conf |m conf |0 PUB:(DE-HGF)6 |s 1719297633_7356 |2 PUB:(DE-HGF) |x After Call |
| 520 | _ | _ | |a Objectives: The piperazine scaffold is a privileged structuralmotif contained in numerous pharmaceuticals, including severalPET-tracers. The aim of this work was to evaluate quaternary DABCOsalts as precursors for the preparation of probes containing a N-(2-[18F]Fluoroethyl)piperazyl fragment by the “minimalist” approach.[1]The latter allows for the preparation of 18F-labeled compounds usingonly [18F]F– and onium salt precursors, obviating the need for externalbase, other additives and azeotropic drying.Methods: Quaternary DABCO salts were prepared by direct alkylation,(het)arylation, benzoylation or tosylation of DABCO. If necessary,anion metathesis was carried out. [18F]F– was eluted from ananion exchange resin with a solution of the corresponding DABCO saltin MeOH. MeOH was evaporated at 60°C for 8 min, the residue wastaken up into a suitable solvent and heated in a Monowave 50 (AntonPaar, Ostfildern-Scharnhausen, Germany) synthesis reactor. The radiolabelingprocedure was optimized with respect to reaction time,temperature, solvent and DABCO salt counter ion. Radiolabeled compoundsprepared from alkyl-substituted DABCO salts were isolatedby solid phase extraction (SPE). Additionally, N-(2-[18F]Fluoroethyl)-N’-pentynyl-piperazine ([18F]1) isolated by SPE was clicked withbenzyl azide (2) to afford a 18F-fluorinated model triazole ([18F]3).Results: Reaction of DABCO with alkyl halogenides or sulfonatesled to quaternary alkyl DABCO salts, radiofluorination of which under“minimalist” conditions furnished the corresponding ring openingproducts, N-alkyl-N’-(2-[18F]Fluoroethyl) piperazines, in 48–93%RCYs (determined by HPLC) and, after isolation by simple SPE, activityyields of up to 31%. Reaction of [18F]1 with 2 delivered [18F]3 in aquantitative RCY (determined by HPLC). (Het)arylation, benzoylationand tosylation of DABCO afforded the respective N’-substituted piperazyl-N-ethyl DABCO salts (addition products of two DABCO molecules)in up to 90% yields as single isolable products. 18F-Fluorinationof such substrates mainly occurred via substitution of the DABCOgroup, leading to formation of the corresponding radiofluorinatedN-substituted N’-(2-[18F]Fluoroethyl)piperazines in RCYs of 28–46%(determined by HPLC).Conclusions: Quaternary DABCO salts are efficient precursors forrapid preparation of probes containing an N-(2-[18F]Fluoroethyl)piperazinemotif using the simple and convenient “minimalist” protocol.Acknowledgement: This work was supported by the DFG grantZL 65/4-1.Reference:[1] B. D. Zlatopolskiy, et al.; Org. Biomol. Chem., 2014, 12, 8094. |
| 536 | _ | _ | |a 5253 - Neuroimaging (POF4-525) |0 G:(DE-HGF)POF4-5253 |c POF4-525 |f POF IV |x 0 |
| 588 | _ | _ | |a Dataset connected to CrossRef, Journals: juser.fz-juelich.de |
| 700 | 1 | _ | |a Zlatopolskiy, Boris |0 P:(DE-Juel1)185610 |b 1 |u fzj |
| 700 | 1 | _ | |a Neumaier, Bernd |0 P:(DE-Juel1)166419 |b 2 |u fzj |
| 773 | _ | _ | |a 10.1016/S0969-8051(22)00134-2 |0 PERI:(DE-600)1498538-X |y 2022 |g Vol. 108-109, p. S49 - |x 0969-8051 |
| 856 | 4 | _ | |u https://juser.fz-juelich.de/record/911349/files/1-s2.0-S0969805122001342-main.pdf |y Restricted |
| 856 | 4 | _ | |u https://juser.fz-juelich.de/record/911349/files/1-s2.0-S0969805122001342-main.gif?subformat=icon |x icon |y Restricted |
| 856 | 4 | _ | |u https://juser.fz-juelich.de/record/911349/files/1-s2.0-S0969805122001342-main.jpg?subformat=icon-1440 |x icon-1440 |y Restricted |
| 856 | 4 | _ | |u https://juser.fz-juelich.de/record/911349/files/1-s2.0-S0969805122001342-main.jpg?subformat=icon-180 |x icon-180 |y Restricted |
| 856 | 4 | _ | |u https://juser.fz-juelich.de/record/911349/files/1-s2.0-S0969805122001342-main.jpg?subformat=icon-640 |x icon-640 |y Restricted |
| 909 | C | O | |o oai:juser.fz-juelich.de:911349 |p VDB |
| 910 | 1 | _ | |a Forschungszentrum Jülich |0 I:(DE-588b)5008462-8 |k FZJ |b 0 |6 P:(DE-Juel1)186812 |
| 910 | 1 | _ | |a Forschungszentrum Jülich |0 I:(DE-588b)5008462-8 |k FZJ |b 1 |6 P:(DE-Juel1)185610 |
| 910 | 1 | _ | |a Forschungszentrum Jülich |0 I:(DE-588b)5008462-8 |k FZJ |b 2 |6 P:(DE-Juel1)166419 |
| 913 | 1 | _ | |a DE-HGF |b Key Technologies |l Natural, Artificial and Cognitive Information Processing |1 G:(DE-HGF)POF4-520 |0 G:(DE-HGF)POF4-525 |3 G:(DE-HGF)POF4 |2 G:(DE-HGF)POF4-500 |4 G:(DE-HGF)POF |v Decoding Brain Organization and Dysfunction |9 G:(DE-HGF)POF4-5253 |x 0 |
| 915 | _ | _ | |a Nationallizenz |0 StatID:(DE-HGF)0420 |2 StatID |d 2021-01-30 |w ger |
| 915 | _ | _ | |a DBCoverage |0 StatID:(DE-HGF)0200 |2 StatID |b SCOPUS |d 2021-01-30 |
| 915 | _ | _ | |a DBCoverage |0 StatID:(DE-HGF)0300 |2 StatID |b Medline |d 2021-01-30 |
| 915 | _ | _ | |a DBCoverage |0 StatID:(DE-HGF)0199 |2 StatID |b Clarivate Analytics Master Journal List |d 2021-01-30 |
| 915 | _ | _ | |a DBCoverage |0 StatID:(DE-HGF)1030 |2 StatID |b Current Contents - Life Sciences |d 2021-01-30 |
| 915 | _ | _ | |a DBCoverage |0 StatID:(DE-HGF)0160 |2 StatID |b Essential Science Indicators |d 2021-01-30 |
| 915 | _ | _ | |a DBCoverage |0 StatID:(DE-HGF)1050 |2 StatID |b BIOSIS Previews |d 2021-01-30 |
| 915 | _ | _ | |a DBCoverage |0 StatID:(DE-HGF)1190 |2 StatID |b Biological Abstracts |d 2021-01-30 |
| 915 | _ | _ | |a WoS |0 StatID:(DE-HGF)0113 |2 StatID |b Science Citation Index Expanded |d 2021-01-30 |
| 915 | _ | _ | |a DBCoverage |0 StatID:(DE-HGF)0150 |2 StatID |b Web of Science Core Collection |d 2021-01-30 |
| 915 | _ | _ | |a JCR |0 StatID:(DE-HGF)0100 |2 StatID |b NUCL MED BIOL : 2019 |d 2021-01-30 |
| 915 | _ | _ | |a DBCoverage |0 StatID:(DE-HGF)0600 |2 StatID |b Ebsco Academic Search |d 2021-01-30 |
| 915 | _ | _ | |a Peer Review |0 StatID:(DE-HGF)0030 |2 StatID |b ASC |d 2021-01-30 |
| 915 | _ | _ | |a IF < 5 |0 StatID:(DE-HGF)9900 |2 StatID |d 2021-01-30 |
| 920 | _ | _ | |l yes |
| 920 | 1 | _ | |0 I:(DE-Juel1)INM-5-20090406 |k INM-5 |l Nuklearchemie |x 0 |
| 980 | _ | _ | |a conf |
| 980 | _ | _ | |a VDB |
| 980 | _ | _ | |a I:(DE-Juel1)INM-5-20090406 |
| 980 | _ | _ | |a UNRESTRICTED |
| Library | Collection | CLSMajor | CLSMinor | Language | Author |
|---|